# Nina Shah

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nina-shah/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,041 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 53 |
| i10-index | 195 |
| Last Known Institution | Kaiser Permanente |
| OpenAlex ID | https://openalex.org/A5053904944 |
| ORCID iD | 0000-0002-1971-8173 |
| Works | 527 |

## Researcher papers

- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial](https://scholariq.org/papers/daratumumab-lenalidomide-bortezomib-and-dexamethasone-for-transplant-eligible/)
- [B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches](https://scholariq.org/papers/b-cell-maturation-antigen-bcma-in-multiple-myeloma-rationale-for-targeting-and/)
- [Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture](https://scholariq.org/papers/cord-blood-engraftment-with-ex-vivo-mesenchymal-cell-coculture/)
- [Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial](https://scholariq.org/papers/autologous-transplantation-consolidation-and-maintenance-therapy-in-multiple/)
- [Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma](https://scholariq.org/papers/phase-i-study-of-cord-blood-derived-natural-killer-cells-combined-with/)
- [Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy](https://scholariq.org/papers/augmented-her-2-specific-immunity-during-treatment-with-trastuzumab-and/)
- [Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD](https://scholariq.org/papers/regulatory-b-cells-are-enriched-within-the-igm-memory-and-transitional-subsets/)
- [Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity](https://scholariq.org/papers/antigen-presenting-cell-mediated-expansion-of-human-umbilical-cord-blood-yields/)
- [Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee](https://scholariq.org/papers/personalizing-busulfan-based-conditioning-considerations-from-the-american/)
- [Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial](https://scholariq.org/papers/analysis-of-patient-reported-experiences-up-to-2-years-after-receiving/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Kaiser Permanente](https://scholariq.org/institutions/kaiser-permanente/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.